Format

Send to

Choose Destination
J Biomed Semantics. 2017 Jan 10;8(1):2. doi: 10.1186/s13326-016-0110-0.

Toward a comprehensive drug ontology: extraction of drug-indication relations from diverse information sources.

Author information

1
Scientific Information Management, Merck Research Laboratories, 770 Sumneytown Pike, West Point, Philadelphia, PA, 19486, USA. sharp@merck.com.

Abstract

BACKGROUND:

Drug ontologies could help pharmaceutical researchers overcome information overload and speed the pace of drug discovery, thus benefiting the industry and patients alike. Drug-disease relations, specifically drug-indication relations, are a prime candidate for representation in ontologies. There is a wealth of available drug-indication information, but structuring and integrating it is challenging.

RESULTS:

We created a drug-indication database (DID) of data from 12 openly available, commercially available, and proprietary information sources, integrated by terminological normalization to UMLS and other authorities. Across sources, there are 29,964 unique raw drug/chemical names, 10,938 unique raw indication "target" terms, and 192,008 unique raw drug-indication pairs. Drug/chemical name normalization to CAS numbers or UMLS concepts reduced the unique name count to 91 or 85% of the raw count, respectively, 84% if combined. Indication "target" normalization to UMLS "phenotypic-type" concepts reduced the unique term count to 57% of the raw count. The 12 sources of raw data varied widely in coverage (numbers of unique drug/chemical and indication concepts and relations) generally consistent with the idiosyncrasies of each source, but had strikingly little overlap, suggesting that we successfully achieved source/raw data diversity.

CONCLUSIONS:

The DID is a database of structured drug-indication relations intended to facilitate building practical, comprehensive, integrated drug ontologies. The DID itself is not an ontology, but could be converted to one more easily than the contributing raw data. Our methodology could be adapted to the creation of other structured drug-disease databases such as for contraindications, precautions, warnings, and side effects.

KEYWORDS:

Drug indications; Drug information integration; Drug ontologies; Drug-disease relations; UMLS; WHO-ATC

PMID:
28069052
PMCID:
PMC5223332
DOI:
10.1186/s13326-016-0110-0
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center